sponsored
PatientsVille.com Logo

PatientsVille

Polymyositis Medical Research Studies

Up-to-date List of Polymyositis Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Polymyositis Medical Research Studies

Rank Status Study
1 Recruiting Acthar in Treatment of Refractory Dermatomyositis and Polymyositis
Conditions: Dermatomyositis;   Polymyositis
Intervention: Drug: Adrenocorticotropic Hormone Gel
Outcome Measures: Specific Aim 1: To determine the efficacy of H.P. Acthar Gel in refractory adult PM and DM patients defined by the IMACS preliminary definition of improvement (DOI).;   To assess the safety, tolerability, and steroid-sparing effect of H.P. Acthar Gel in refractory adult PM and DM patients.
2 Recruiting Efficacy and Tolerability of BAF312 in Patients With Polymyositis
Condition: Polymyositis
Interventions: Drug: Placebo;   Drug: BAF312
Outcome Measures: Combined efficacy endpoint: Manual Muscle Testing (MMT) and serum creatine kinase (CK) levels;   Adverse Events
3 Not yet recruiting Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis
Conditions: Dermatomyositis;   Polymyositis
Interventions: Drug: tocilizumab;   Drug: Placebo
Outcome Measures: Proportion of subjects meeting the definition of improvement (DOI);   Comparison of the time to first DOI between the 2 arms;   frequency of defined adverse events between the treatment and placebo arms.
4 Unknown  Abatacept Treatment in Polymyositis and Dermatomyositis
Conditions: Polymyositis;   Dermatomyositis
Intervention: Drug: Abatacept
Outcome Measures: The number of responders, defined as improved according the IMACS criteria;   The change in the individual components of the IMACS core set measures for disease activity
5 Unknown  Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis
Conditions: Dermatomyositis;   Polymyositis
Intervention: Other: Active rehabilitation
Outcome Measures: HAQ score;   Quality of life (SF36 score);   MFM(motor function measure);   muscle strength (MRC manual muscle testing)
6 Recruiting Study and Treatment of Inflammatory Muscle Diseases
Conditions: Autoimmune Disease;   Dermatomyositis;   Inclusion Body Myositis;   Myositis;   Polymyositis
Intervention:
Outcome Measure:
7 Recruiting A Survey for Long-term Use of Prograf Capsules in Patient With Interstitial Pneumonia
Condition: Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis
Intervention: Drug: Prograf
Outcome Measures: Overall survival;   Respiratory function test value (%FVC, %DLco);   Arterial blood gas analysis value (PaO2, AaDO2);   Chest CT findings;   Serum KL-6 value (serum SP-D value);   Patient disposition;   Safety assessed by the incidence of adverse events
8 Recruiting Dermatomyositis and Polymyositis Registry
Conditions: Dermatomyositis;   Polymyositis
Intervention: Drug: Acthar
Outcome Measures: Determining if Acthar treatment improves disease progression;   Subgroups may predict response to Acthar therapy
9 Recruiting Investigating Genes in Patients With Polymyositis and Dermatomyositis
Condition: Myositis
Intervention: Procedure: Venepuncture
Outcome Measure: To identify any disease susceptibility genes associated with development and clinical characteristics of primary inflammatory muscle diseases, PM, DM and IBM.
10 Recruiting Environmental Risk Factors for Myositis in Military Personnel
Conditions: Dermatomyositis;   Adult Polymyositis;   Inclusion Body Myositis;   Myositis
Intervention:
Outcome Measure: Military Myositis Questionnaire
11 Recruiting Adult and Juvenile Myositis
Conditions: Dermatomyositis;   Polymyositis;   Inclusion Body Myositis
Intervention:
Outcome Measure:
12 Recruiting Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory Myopathies
Conditions: Myositis;   Polymyositis;   Dermatomyositis;   Myositis, Inclusion Body
Intervention: Procedure: MRI-oriented muscle biopsy
Outcome Measures: Evaluation of T1 and STIR (Short Tau Inversion Recovery) sequences of muscle MRI.;   Presence of IIM diagnosed by muscle biopsy;   Evaluation of reproductibility intra- versus inter-observers for muscle biopsy interpretation;   Evaluation of reproductibility intra- versus inter-observers for muscle MRI interpretation
13 Not yet recruiting Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD
Conditions: Interstitial Lung Disease;   Scleroderma;   Idiopathic Inflammatory Myositis;   Mixed Connective Tissue Disease
Interventions: Drug: Rituximab;   Drug: Cyclophosphamide
Outcome Measures: Absolute change in FVC;   • Change from baseline in diffusing capacity for carbon monoxide (DLco);   • Change from baseline in health related quality of life scores;   • Change from baseline in global disease activity score;   • Progression free survival;   • Adverse and serious adverse events (as defined in GCP)
14 Unknown  Detection of Pompe Disease in Adult Patients With Myopathies of Uncertain Origin or With Asymptomatic Hyper-CK-emia
Condition: Pompe Disease
Intervention:
Outcome Measure:
15 Unknown  A Case-control Study to Assess Risk of Coronary Heart Disease in Idiopathic Inflammatory Myopathy
Condition: Idiopathic Inflammatory Myopathy
Intervention:
Outcome Measure:
16 Unknown  Evaluating N-Acetylcysteine in CTD-ILD Treatment
Conditions: Interstitial Lung Disease;   Connective Tissue Disease
Intervention: Drug: N-Acetylcysteine
Outcome Measures: Assess the tolerability and safety of N-acetylcysteine (NAC) in patients with connective tissue disease related interstitial lung disease (CTD-ILD).;   Evaluate the efficacy of NAC in patients with CTD-ILD.;   Assess serum matrix metalloproteinase (MMP) levels as a potential biomarker.
17 Unknown  Infections and Autoimmunity: Autobodies Screening in Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Procedure: Serum antibodies to infectious agents using the BioPlex 2200 and complementary EIA kits
Outcome Measures: Determine antibodies to infectious agents immunoglobulin G (IgG), IgM in patients with multiple sclerosis;   Assess correlation between antibody levels to various infectious agents with clinical disease variables
18 Recruiting Pulmonary Fibrosis Contact Registry
Conditions: Pulmonary Fibrosis of Any Cause;   Primary Supporters/Caretakers of Patients With Pulmonary Fibrosis
Intervention:
Outcome Measure: Number enrolled
19 Unknown  A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis
Condition: Dermatomyositis
Intervention: Drug: Apremilast
Outcome Measures: The primary endpoint analysis will be safety, as measured by the number of adverse events and serious adverse events occuring during 12 weeks of therapy and 4 weeks of followup.;   The secondary outcome measure will be efficacy, as measured by the number of participants experiencing a 30% decreased in the CDASI-a score at 12 weeks.
20 Unknown  Creatine Supplementation in Pediatric Rheumatology
Conditions: Juvenile Systemic Lupus Erythematosus;   Juvenile Dermatomyositis
Interventions: Dietary Supplement: creatine;   Dietary Supplement: placebo (dextrose)
Outcome Measures: muscle strength;   kidney function parameters;   quality of life;   muscle function

These studies may lead to new treatments and are adding insight into Polymyositis etiology and treatment.

A major focus of Polymyositis research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Polymyositis